Why Haemonetics is on investors’ radar today Haemonetics (HAE) is drawing attention after recent share performance that includes a month decline of about 3% and a past 3 months drop of roughly 24%, ...

Haemonetics ( (HAE)) has shared an announcement. On March 2, 2026, Haemonetics Corporation fully repaid at maturity its outstanding 0.00% Convertible Senior Notes due 2026, paying $300 million in cash ...

Haemonetics’s 21.4% return over the past six months has outpaced the S&P 500 by 15.6%, and its stock price has climbed to $65 ...

Haemonetics, which concentrates on hematology products and services, booked revenue of $327 million for the quarter. Although that was 5% down year over year, it handily topped the average analyst ...

The largest contributor was Haemonetics Corp., a medical device company focused on products related to blood collection and management.

Haemonetics (NYSE: HAE) announced that it received FDA approval for its NexSys PCS plasma collection system with Persona PLUS ...

BOSTON, Nov. 6, 2025 /PRNewswire/ -- Haemonetics Corporation (NYSE: HAE) announced that financial results for its second quarter fiscal year 2026, which ended September 27, 2025, are available on the ...

Haemonetics (NYSE:HAE) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments, the table ...

9 analysts have shared their evaluations of Haemonetics (NYSE:HAE) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table summarizes their recent ...

BOSTON, May 23, 2024 /PRNewswire/ -- Haemonetics Corporation (HAE) today announced the pricing of its offering of $600,000,000 aggregate principal amount of 2.50% Convertible Senior Notes due 2029 ...

Haemonetics is dropping at least $160 million to acquire the maker of a system designed to cool down and protect the esophagus from errant damage during cardiac ablation procedures aimed at ...